

LLC - Etude épidémiologique

Dr Zriba Sami


JOURNÉE SCIENTIFIQUE

Référentiel de traitement de la leucémie lymphoïde
chronique


(Groupe de Réflexion LLC)


11/04/2014

N=246



Sex ratio 169/77 = 2,2
Age médian = 66 ans (23-92)






Année du diagnostic

| année | Nombre (%) |
|-------|------------|
| 2009 | 51 (20,7) |
| 2010 | 68 (27,6) |
| 2011 | 69 (28,1) |
| 2012 | 58 (23,6) |


| | |
|-----------------------------|------------------|
| ATCD Fx de néoplasie | 12 (4,9%) |
| ATCD Pls de néoplasie | 27 (11%) |



CDD



Délai symptômes/diagnostic :
médiane= 2 mois [1-78]

Présentation clinique







- ADP cervicales
- ADP axillaires
- ADP inguinales


NFS

| | | |
|-----|---------|-----------------|
| GB | 49 700 | [7 500-900 000] |
| Lc | 42 250 | [4 500-870 000] |
| PNN | 4 700 | [850-25 000] |
| Hb | 11,4 | [3,4-16,3] |
| PLQ | 172 000 | [2 000-478 000] |



IP





BOM
7%

- Matutes 3

Biopsie gg
10%

- Avant 1^{ère} consultation
- Difficulté diagnostique
- Richtérisation

Etude cytogénétique: 24,8%

FISH: 64%

| Anomalie cytogénétique | Nombre |
|------------------------|--------|
| +12 | 8 |
| 13q- | 8 |
| 17p- | 4 |
| 11q- | 2 |
| 6q- | 1 |
| Complexe | 1 |
| -Y | 1 |
| t(2,14) | 1 |
| +17 | 1 |
| +13 | 1 |
| -2 | 1 |
| Anomalies 9,10 | 1 |

A horizontal bar chart with three rows. Each row consists of a blue rounded rectangle on the left and a white rectangle with a blue border on the right. The blue rectangles contain the following text: 'TCD 80%', 'TCD+: 11,3%', and 'Hémolyse 41%'. The white rectangles are empty.

| Category | Percentage |
|----------|------------|
| TCD | 80% |
| TCD+ | 11,3% |
| Hémolyse | 41% |

TCD 80%

TCD+: 11,3%

Hémolyse 41%


Béta2m: 25/64

- LDH: 53/185

EPP: hypogamma 39/135, pic
3/135

- Cl créat ≥ 70 ml/min 74%


Binet



Symptômes B: 19%


Signes d'activité: 39%

Traitement




Temps de latence médian = 9 mois (2-36)


Traitement




OS





Survie globale à 5 ans = 70%








Recul en mois



Recul en mois







Remerciements

Groupe de réflexion sur la LLC

Pr Zouari Béchir